1CP
REGN icon

1015 Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

1015 Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6K Buy
17
+1
+6% +$681 0.01% 226
2026
Q1 		$12.4K Hold
16
– – 0.01% 221
2025
Q4 		$12.3K Buy
+16
New +$10.9K 0.01% 217

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

1015 Capital Partners's REGN Position: Q2 2026 in Review

1015 Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 6.3% in Q2 2026, buying an estimated $681 and bringing the position to 17 shares worth $10.6K. The position accounts for 0.01% of the portfolio, ranked #226.

1015 Capital Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.4K in Q1 2026. 1,326 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • 1015 Capital Partners held 17 shares of Regeneron Pharmaceuticals worth $10.6K as of Q2 2026.
  • 1015 Capital Partners bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
  • Regeneron Pharmaceuticals made up 0.01% of 1015 Capital Partners's portfolio in Q2 2026, its #226 holding.
  • 1015 Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1015 Capital Partners's Regeneron Pharmaceuticals position peaked at $12.4K in Q1 2026.
  • 1,326 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.